BSECompany Update2d ago · 12 Oct 2026, 03:24 pm
Compliance Certificate Under Regulation 74 (5) for the Period ended 30th September, 2026
Bacil Pharma Ltd · 524516
✦ AI Summary
Bacil Pharma Ltd has submitted a compliance certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the period ended 30th September, 2026, confirming the dematerialization of securities and listing on stock exchanges.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Bacil Pharma Ltd - 524516 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Attachments (1)
📄pdf
Download →
fb2c0277-dfa7-4b27-b664-334c7e54762f.pdf
View document text
Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099
Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541,
Tel/Fax: 22618327
Date: 12-10-2026
The Manager (Listing),
BSE Limited
PJ Tower, Dalal Street,Fort, Mumbai – 400 001
Sub: Submission of copy of Certificate under Regulation 74 (5) of the SEBI (Depositories and
Participants) Regulations, 2018 for the period ended 30th September, 2026
Ref.: Scrip Code: 524516, Stock Code: BACPHAR
Dear Sir,
We enclose herewith copy of certificate received from Bigshare Services Pvt. Ltd., Registrar and
Transfer Agent of the company under above Regulations, certifying the following:-
1. The securities comprised in the certificate(s) of Security dematerialised, have been listed on stock
exchanges where the earlier issued securities are listed.
2. After due verification, immediately mutilated and cancelled the certificate(s) of security received
for dematerialisation.
3. Substituted in our records the name of the Depository as the registered owner and had sent a
certificate to this effect to the Depositories and to every stock exchange on a quarterly basis, where
the security is listed.
Kindly find the same in order and acknowledge the receipt.
For Bacil Pharma Limited
Chaitali Kalpataru Shah
Managing Director
Din: 11167778
Ref No. BSS/74(5)
Date: 08/10/2026
BACIL PHARMA LTD
71 LAXMI BUILDING
4TH FLOOR SIR P M ROAD
FORT
MUMBAI- 400001
Dear Sir/Madam,
Sub: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations,
2018 for the quarter ended 30th September 2026.
Ref: NSDL/CIR/II/5/2019 dated 25th January 2019 DSL/OPS/RTA/POLICY/2019/14 dated 25th
January 2019. SEBI vide its letter ref no. MRD/DOP2/DSA2/OW/2019/2498/1 dated 24/01/2019
In reference to the above – captioned regulation we hereby confirm that the securities received from the
depository Participants for dematerialization up to 30th September 2026, were confirmed
(accepted/rejected) to the depositories by us and that securities comprised in the said certificates have
been listed on the stock exchange where the earlier issued securities are listed.
We hereby confirm that the security certificates received for dematerialization have been mutilated &
cancelled after due verification by the depository Participant and the name of the depositories have been
substituted in register of members as registered owner within 15 days of receipt of certificate of
securities.
We request you to kindly take note of the above in your records.
Thanking you,
Yours faithfully,
For Bigshare Services Pvt. Ltd.,
Sandeep More
Authorised Signatory